§4.2 — Proposition 1 persists under outcome-based payment
ProvedRareDisease.Endogenous.proposition_1_outcomeoptimal-policyoutcome-based-paymentp2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1subsidy
Let , , and . In Setting (1B), with manufacturer pricing and outcome-based payment, is optimal and is the only optimal subsidy policy. At every manufacturer best response to that policy, spending equals the budget and patient welfare and manufacturer profit are
This formalizes the paper's statement that Proposition 1 continues to hold for outcome-based payment.
Formalization Note The positivity assumptions make the closed form and best-response optimization nondegenerate. Efficacy ranges over all positive reals, matching the maximization in equation (8).
Preamble
import Mathlib import Definitions.Def_RareDisease_Endogenous_Setting
Formal statement
namespace RareDisease.Endogenous
/-- §4.2, p. 13, after (16): Proposition 1 continues to hold with outcome-based payment. -/
theorem proposition_1_outcome (k B : ℝ) (hk : 0 < k) (hB : 0 < B) :
IsOptimalB k B (alphaStar k B) 0 ∧
(∀ α β : ℝ, IsOptimalB k B α β ↔ α = alphaStar k B ∧ β = 0) ∧
(∀ x ∈ BRB k (alphaStar k B) 0,
spendB k (alphaStar k B) 0 x.1 x.2 = B ∧
welfareB 0 x.1 x.2 = 2 * B / (Real.sqrt (256 * B * k + 1) - 1) ∧
profitB k (alphaStar k B) 0 x.1 x.2 =
2 * B / (Real.sqrt (256 * B * k + 1) - 1)) := by sorry
end RareDisease.Endogenous
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 13, §4.2, paragraph after equation (16)
Human review
Confirmed by the mission captain (proposal self-audit).
Confirmed by the moderator at approval.